Donald Notman Sells 11,119 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 11,119 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Stock Up 4.0 %

OCUL opened at $8.13 on Thursday. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.77. The firm has a 50 day moving average price of $8.57 and a 200 day moving average price of $9.01. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company has a market cap of $1.28 billion, a PE ratio of -6.16 and a beta of 1.22.

Analysts Set New Price Targets

A number of analysts have issued reports on OCUL shares. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank began coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Institutional Investors Weigh In On Ocular Therapeutix

Several large investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its holdings in shares of Ocular Therapeutix by 275.3% during the 2nd quarter. Squarepoint Ops LLC now owns 64,911 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 47,614 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Ocular Therapeutix by 61.5% during the second quarter. The Manufacturers Life Insurance Company now owns 116,964 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 44,524 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Ocular Therapeutix in the second quarter worth about $69,000. Cetera Investment Advisers grew its stake in shares of Ocular Therapeutix by 1.8% in the second quarter. Cetera Investment Advisers now owns 739,044 shares of the biopharmaceutical company’s stock valued at $5,055,000 after buying an additional 13,054 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $393,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.